K. Bui

发表

Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist

Diansong Zhou, K. Bui, Hongmei Xu, 2017, Clinical Pharmacokinetics.

Chapter 10 – Metabolism and pharmacokinetic optimization strategies in drug discovery

P. Ballard, K. Bui, P. Brassil, 2013 .

Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents

Diansong Zhou, Trevor N Johnson, Diansong Zhou, 2014, Biopharmaceutics & drug disposition.

EVIDENCE FOR AN FU ORIONIS-LIKE OUTBURST FROM A CLASSICAL T TAURI STAR

Richard Walters, Adam A. Miller, Viswa Velur, 2010, 1011.2063.

Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients.

K. Bui, Hongmei Xu, N. Al-Huniti, 2016, British journal of clinical pharmacology.

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers

R. Plummer, Karen So, T. Yap, 2018, Journal of clinical pharmacology.

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation

Diansong Zhou, K. Bui, Hongmei Xu, 2017, CPT: pharmacometrics & systems pharmacology.

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation

K. Bui, E. Floettmann, M. Sostek, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol

Diansong Zhou, K. Bui, N. Al-Huniti, 2016, Journal of clinical pharmacology.

Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects

Diansong Zhou, Diansong Zhou, K. Bui, 2015, Journal of clinical pharmacology.

Pharmacokinetics, metabolism and excretion of [14C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects

Diansong Zhou, S. Grimm, K. Bui, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation

P. Conley, K. Bui, J. Curnutte, 2020, Research and practice in thrombosis and haemostasis.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Karen So, A. Dingemans, Yuh-Min Chen, 2018, British journal of clinical pharmacology.

The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol

K. Bui, M. Sostek, F. She, 2014, Journal of clinical pharmacology.

The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

K. Bui, M. Sostek, F. She, 2014, Journal of clinical pharmacology.

Performance characteristics of the Erenna™ cTnI assay for in vitro diagnostic use in the Singulex® Clinical Laboratory

S. Agee, K. Bui, P. Simpson, 2007 .

Short-and Long-Term Cardiac Troponin I Analyte Stability in Plasma and Serum from Healthy

A. Wu, J. Todd, S. Agee, 2022 .

In vitro and in vivo metabolism of a selective δ-opioid receptor agonist

Diansong Zhou, S. Grimm, K. Bui, 2011 .

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

Michael R. Johnson, M. Quirk, J. Zajecka, 2016, Neuropsychopharmacology.

THREE NEW ECLIPSING WHITE-DWARF–M-DWARF BINARIES DISCOVERED IN A SEARCH FOR TRANSITING PLANETS AROUND M-DWARFS

Adam L. Kraus, Suresh Sivanandam, Christoph Baranec, 2011, The Astrophysical Journal.

Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients

Diansong Zhou, H. Tomkinson, K. Bui, 2018, Clinical Pharmacokinetics.

An Open‐Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects

K. Bui, U. Diva, Bruce Berger, 2017, Clinical pharmacology in drug development.

The effect of quinidine, a strong P‐glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol

Diansong Zhou, K. Bui, N. Al-Huniti, 2016, Journal of clinical pharmacology.

Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects

M. Hutchison, K. Bui, M. Sostek, 2015, International journal of clinical pharmacology and therapeutics.

Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending‐dose study

K. Bui, M. Sostek, M. Eldon, 2015, Clinical pharmacology in drug development.

Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder

Diansong Zhou, K. Bui, N. Al-Huniti, 2015, Journal of clinical pharmacology.

Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

Diansong Zhou, K. Bui, Hongmei Xu, 2018, Clinical pharmacology and therapeutics.

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Diansong Zhou, Venkatesh Pilla Reddy, Diansong Zhou, 2018, Clinical pharmacology and therapeutics.

The right compound in the right assay at the right time: an integrated discovery DMPK strategy

Peter Ballard, Patrick Brassil, Khanh H Bui, 2012, Drug metabolism reviews.

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

S. Domchek, Sang-We Kim, F. Barlesi, 2017 .

Efficacy and Safety Exposure‐Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients

Diansong Zhou, H. Tomkinson, K. Bui, 2019, Clinical pharmacology and therapeutics.

Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse

K. Bui, C. Paronis, M. Pietras, 2014, Pharmacology Biochemistry and Behavior.

559 In vitro prediction of potential metabolic drug interactions for seroquel

S. Grimm, K. Bui, K. R. Stams, 1997, Schizophrenia Research.

Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder

K. Bui, D. Zhou, F. Agbo, 2017, Journal of clinical pharmacy and therapeutics.

Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

Karen So, J. Vansteenkiste, P. Dickinson, 2018, British journal of clinical pharmacology.

Combining radio telemetry and automated blood sampling: a novel approach for integrative pharmacology and toxicology studies.

Dennis C Litwin, K. Bui, C. Fonck, 2010, Journal of pharmacological and toxicological methods.

Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.

Jay Liu, J. McCauley, K. Bui, 2012, Bioorganic & medicinal chemistry letters.

4-Piperidin-4-ylidenemethyl-benzamides as δ-opioid receptor agonists for CNS indications: identifying clinical candidates.

Jay Liu, J. McCauley, K. Bui, 2012, Bioorganic & medicinal chemistry letters.

Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications

S. Nyberg, K. Bui, W. Earley, 2013, Current medical research and opinion.

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling

N Al‐Huniti, K. Bui, N. Al-Huniti, 2016, CPT: pharmacometrics & systems pharmacology.

Preclinical Pharmacology of AZD2327: A Highly Selective Agonist of the δ-Opioid Receptor

T J Hudzik, Michael D B Swedberg, K. Bui, 2011, Journal of Pharmacology and Experimental Therapeutics.

Validation of a noninvasive monitor to continuously trend individual responses to hypovolemia

G. Grudic, S. Moulton, D. Macleod, 2017, The journal of trauma and acute care surgery.

PTF10nvg: AN OUTBURSTING CLASS I PROTOSTAR IN THE PELICAN/NORTH AMERICAN NEBULA

Nathaniel R. Butler, Richard Walters, Adam A. Miller, 2010, 1011.2565.

In Vitro and In Vivo Metabolism of a Selective δ-Opioid Receptor

Diansong Zhou, S. Grimm, K. Bui, 2011, Drug Metabolism and Disposition.

Mechanistic investigation of N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide-induced insulin depletion in the rat and RINm5F cells.

F. Pognan, K. Bui, M. Otieno, 2008, Toxicological sciences : an official journal of the Society of Toxicology.

Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse

K. Bui, C. Paronis, M. Pietras, 2014, Pharmacology Biochemistry and Behavior.

Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.

K. Bui, D. McCarthy, Yun Alelyunas, 2010, Bioorganic & medicinal chemistry letters.

Short- and long-term cardiac troponin I analyte stability in plasma and serum from healthy volunteers by use of an ultrasensitive, single-molecule counting assay.

A. Wu, J. Todd, S. Agee, 2009, Clinical Chemistry.

Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.

Karen So, J. Vansteenkiste, P. Dickinson, 2016 .

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation

K. Bui, M. Sostek, M. Eldon, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol

K. Bui, M. Sostek, M. Eldon, 2015, Clinical pharmacology in drug development.

The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

K. Bui, M. Sostek, F. She, 2014, Journal of clinical pharmacology.

Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291

R. Plummer, Karen So, E. Lisbon, 2015 .